Ranked by 2024 Global Sales: 1 Ozempic (semaglutide) $16.7 Bn | Novo Nordisk 2 Mounjaro (tirzepatide) $11.5 Bn | Eli Lilly 3 Jardiance (empagliflozin) $9.5 Bn | Boehringer Ingelheim & Eli Lilly 4 Forxiga (dapagliflozin) $7.7 Bn | AstraZeneca 5 Trulicity (dulaglutide) $5.3 Bn | Eli Lilly 6 Rybelsus (semaglutide) $3.2 Bn | Novo Nordisk 7 Humalog (insulin lispro) $2.3 Bn | Eli Lilly 8 NovoRapid (insulin aspart) $2.3 Bn | Novo Nordisk 9 Jentadueto / Trajenta (linagliptin) $1.8 Bn | Boehringer Ingelheim Lantus (insulin glargine) $1.7 Bn | Sanofi Key Insight: The dominance of incretin-based therapies underscores a clear industry shift toward multi-benefit, patient-centric treatments
A: Tirzepatide Injection is administered subcutaneously, typically in the abdomen, thigh, or upper arm, as directed by a healthcare professional
More serious but less common adverse effects observed across the incretin drug class and under investigation for retatrutide include: Pancreatitis : Seek urgent medical attention if you experience severe, persistent abdominal pain, particularly if it radiates to the back
Rybelsus (semaglutide) is an oral medication licensed in the UK for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise
Discuss any concerns with your PlexusDx provider before starting
Supplements and complementary approaches Several supplements show evidence for heartburn management